Evogene Ltd.
EVGN
$1.06
$0.010.47%
NASDAQ
| 06/30/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 884.00K | 1.61M | 1.74M | -1.90M | 3.77M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 884.00K | 1.61M | 1.74M | -1.90M | 3.77M |
| Cost of Revenue | 136.00K | 755.00K | 1.04M | 336.00K | 511.00K |
| Gross Profit | 748.00K | 856.00K | 698.00K | -2.23M | 3.26M |
| SG&A Expenses | 1.50M | 2.02M | 3.31M | 1.38M | 2.38M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | 500.00K | -- | -- | -- |
| Total Operating Expenses | 3.96M | 6.68M | 7.66M | 3.44M | 7.95M |
| Operating Income | -3.07M | -5.07M | -5.92M | -5.34M | -4.18M |
| Income Before Tax | -4.68M | 2.00K | -6.75M | -5.21M | -3.86M |
| Income Tax Expenses | 1.00K | 7.00K | 1.00K | -- | -5.00K |
| Earnings from Continuing Operations | -4.68M | -5.00K | -6.75M | -5.21M | -3.86M |
| Earnings from Discontinued Operations | -- | -- | -1.47M | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 219.00K | 432.00K | 589.00K | 566.00K | -126.00K |
| Net Income | -4.46M | 427.00K | -7.63M | -5.42M | -3.98M |
| EBIT | -3.07M | -5.07M | -5.92M | -5.34M | -4.18M |
| EBITDA | -2.78M | -4.47M | -5.71M | -5.28M | -3.52M |
| EPS Basic | -0.62 | 0.06 | -1.31 | -1.06 | -0.81 |
| Normalized Basic EPS | -0.27 | 0.02 | -- | -- | -0.52 |
| EPS Diluted | -0.62 | 0.06 | -1.31 | -1.06 | -0.81 |
| Normalized Diluted EPS | -0.27 | 0.02 | -- | -- | -0.52 |
| Average Basic Shares Outstanding | 7.23M | 6.80M | 5.81M | 5.09M | 4.89M |
| Average Diluted Shares Outstanding | 7.23M | 6.80M | 5.81M | 5.09M | 4.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |